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Abstract
Objective To investigate whether exposure to spironolactone treatment
affects the risk of incident breast cancer in women over 55 years of age.
Design Retrospective, matched cohort study.
Setting General Practice Research Database, a primary care
anonymised database representative of the general population in the
United Kingdom.
Participants 1 290 625 female patients, older than 55 years and with
no history of breast cancer, from 557 general practices with a total
follow-up time of 8.4 million patient years. We excluded patients with
poor quality data and those with no contacts with their general practitioner
after their current registration date.
Intervention Exposed cohort included women who received at least
two prescriptions of spironolactone after age 55 years, who were followed
up from the first prescription (index date). We randomly selected two
unexposed female controls for every exposed patient, matched by
practice, year of birth, and socioeconomic scores (if information was
available), and followed up from the same date.
Main outcomemeasureNew cases of breast cancer, using Read codes
to confirm diagnoses.
Results Index dates for study patients ranged from 1987 to 2010, and
29 491 new cases of breast cancer were recorded in the study population
(incidence rate 0.35% per year). The exposed cohort of 28 032 patients
and control cohort of 55 961 patients had unadjusted incidence rates of
0.39% and 0.38% per year, respectively, over a mean follow-up time of
4.1 years. Time-to-event analysis, adjusting for potential risk factors,
provided no evidence of an increased incidence of breast cancer in
patients exposed to spironolactone (hazard ratio 0.99, 95% confidence
interval 0.87 to 1.12).
Conclusions These data suggest that the long term management of
cardiovascular conditions with spironolactone does not increase the risk
of breast cancer in women older than 55 years with no history of the
disease.
Introduction
The aldosterone antagonist, spironolactone, is widely used to
treat chronic conditions including cardiovascular conditions
and liver disease in patients in the United Kingdom. In
particular, long term prescription of spironolactone for heart
failure and hypertension has increased markedly over the past
10-12 years. For heart failure, this increase followed the
publication of the Randomised Aldactone Evaluation Study
(RALES), which showed that spironolactone improved survival
in patients with severe left ventricular failure.1 For hypertension,
the recently updated2 and previous versions of guidelines from
the National Institute for Health and Clinical Excellence (NICE)
and British Hypertension Society3 suggest spironolactone as an
option in the treatment of resistant hypertension. However,
despite its increasing use in this specialty, spironolactone is not
currently licensed for the treatment of hypertension in the UK;
the licence was withdrawn in 1988 after concerns of malignancy
in animal models.4 The British National Formulary’s entry for
spironolactone still carries a caution: “potential metabolic
products carcinogenic in rodents.”5 The recent NICE guideline
for hypertension suggests that doctors should seek informed
consent from patients before prescribing spironolactone for
hypertension, despite it now being the recommended first choice
treatment for resistant hypertension.
The metabolism of spironolactone is complex and poorly
understood in humans, but it is believed to have a number of
potentially active metabolites, including canrenone and two
sulphur containing metabolites, 7-α-thiomethylspirolactone and
6-β-hydroxy-7-α-thiomethylspirolactone.6 In addition to its
actions on the mineralocorticoid receptor, spironolactone,
directly or via its metabolites, also acts on other steroid receptors
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including via antiandrogenic and progestogenic routes. A
common side effect of spironolactone is gynaecomastia, which
is thought to be due to the drug’s effects on these receptors. The
other available aldosterone antagonist, eplerenone, is more
specific than spironolactone for the mineralocorticoid receptor
and is likely to have fewer other hormonally based effects, but
it is also less potent7 and much less commonly prescribed in the
UK.
Breast cancer is the most common cancer in women, and about
80% of cases are hormonally dependent (usually oestrogen
receptor positive). Because of the other effects of spironolactone
on the breast (tenderness in women and gynaecomastia in men)
and the known antiandrogenic and progestogenic actions, there
has always been a concern that spironolactone could promote
breast cancer development. Anecdotally, many doctors avoid
prescribing spironolactone to patients with a history of breast
cancer or at high risk of breast cancer since published reports
expressed concern that the drug could increase the risk of breast
cancers and other cancers in humans.8-10However, other studies
have shown no increased risk and overall, studies in this area
have been small and limited.11-15
Many other factors are known to be associated with increased
risk of breast cancer. These factors include age, sex (only 0.5%
of cases occur in men), alcohol use, smoking, postmenopausal
obesity, age at menarche, age at first child, age at menopause,
parity, breastfeeding, use of exogenous oestrogens (such as
hormone replacement therapy or combined oral contraceptive
pill), family history, and in some cases, germline mutations
(such asBRCA1). Patients who receive spironolactone treatment
in the long term for hypertension or heart failure tend to be
older, and this is also the group of patients most at risk of breast
cancer. We aimed to investigate whether exposure to
spironolactone affects the risk of incident breast cancer in
women over 55 years of age in the UK.
Methods
Study design and hypothesis
We did a retrospective cohort study using the General Practice
Research Database. This longitudinal database contains details
of patients’ demographics, medical diagnoses, referrals to
consultants and hospitals, and primary care prescriptions from
a representative sample of general practices in the UK.16 The
study protocol was reviewed and approved by the independent
scientific advisory committee of the database before the study
began. No further ethical approval is required for studies using
the database that do not involve patient contact. We tested a
prespecified hypothesis that exposure to spironolactone is
associated with an increased incidence of breast cancer in
women.
Study population
The study population included all women who contributed
follow-up time to the database after the age of 55 years. The
selected cut-off age is the age at which most women are
postmenopausal and after which breast cancer becomes more
common. Patients with unacceptable quality standard data, as
determined by the General Practice Research Database, and
patients with no contacts with their general practitioner after
their current registration date were considered ineligible for this
study. Eligible follow-up time for the remaining patients started
from the latest date of their current registration date, their
practice’s “up-to-standard” date, or 1 January of the year on
which they reached the age of 55 years. Follow-up ended with
patients’ last consultation date, unless this date was more than
two years later than the penultimate consultation, in which case
we used the contact date instead.
Study cohorts
We defined the exposed cohort as women who received at least
two prescriptions of spironolactone after the age of 55 years.
The date of the first of these prescriptions was defined as the
index date. We constructed a control cohort by randomly
selecting two female patients for every exposed patient who
met the following criteria: registered with the same practice,
and born in the same year (or within five years if no exact
matches were found). In those practices that provided
socioeconomic scores, matched patients also belonged to the
same quintile of the distribution of scores. We assigned control
patients the same index date as the exposed patient to whom
they were matched. Patients who were subsequently exposed
to spironolactone were eligible for inclusion in the control cohort
before this exposure.When used as controls, these patients were
censored at first exposure to spironolactone after the index date
they had been assigned as a control.
We also constructed a control cohort matched on propensity
scores for exposure to spironolactone, but we were unable to
include all the covariates in the estimation of propensity scores
due to non-convergence of the statistical procedures. However,
although the propensity score matched analysis was incomplete,
it did not show different results from the main analysis and is
not reported here.
Outcomes
We used Read codes for confirmed diagnoses of breast cancer,
including breast cancer in situ (table 1⇓). The primary end point
was the first incidence of breast cancer (invasive or in situ) after
the index date. A secondary outcome excluded cases of breast
cancer in situ.
Covariates
Covariates included age, calendar year of entry to study,
Townsend score (socioeconomic status), use of combined oral
contraceptive pill or hormone replacement therapy, history of
benign breast disease, alcohol intake, body mass index, family
history of breast cancer, use of drugs that may protect against
breast cancer (aspirin, metformin), use of drugs causing
gynaecomastia (digoxin, finasteride, cimetidine, nifedipine),
and history of hypertension, heart failure, or diabetes mellitus.
The number of British National Formulary drug classes
prescribed was also included as a measure of general
comorbidity. All covariates were evaluated on each patient’s
index date. We also considered use of eplerenone as a covariate,
but only eight patients in our study cohorts were prescribed it.
Statistical methods
We did time-to-event analyses using the intervals from the index
date to the diagnosis of breast cancer (events) or the end of the
follow-up period (censored observations). Preliminary analyses
suggested that a proportional hazards model was appropriate,
and we therefore presented results as hazard ratios for breast
cancer associated with spironolactone exposure, adjusted for
significant covariates. The significant covariates were identified
by a forward selection process, with the threshold for entry into
the model set at P<0.05. All covariates were entered into the
analysis as continuous variables.
Four covariates were not available for some patients:
socioeconomic score (51 022 (61%) patients in practices that
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did not provide scores), body mass index (unknown in 17 442
(21%) patients), alcohol consumption (unknown in 31 700 (38%)
patients), and maximum dose of spironolactone (dosing
instructions not coded for 2285 (8%) patients in the exposed
cohort). In view of the large proportion of patients affected, we
excluded covariates with missing values from the primary
analysis. We then did separate analyses for the subsets of
patients with and without known values of the socioeconomic
score, body mass index, and alcohol consumption. We also
tested for a dose response to spironolactone, on a dose doubling
scale, within the exposed cohort.
We did a first sensitivity analysis by excluding breast cancer in
situ from the outcomes. In a second sensitivity analysis, we
replaced missing covariate data with imputed values, although
one assumption required by these techniques was not met (that
the covariates had a multivariate normal distribution), and
another might not have been true (that data were missing at
random). A third sensitivity analysis used propensity scores to
match patients within practices. Potential control patients were
assigned index dates at random from the distribution of index
dates in exposed patients. We evaluated all covariates on these
dates, and estimated the probability of exposure to
spironolactone using as many of these covariates as possible.
The socioeconomic score was necessarily excluded in practices
that did not provide it. Statistical analyses were done using SAS
version 9.1.
Results
Study population
The study population consisted of 1 290 625 patients from 557
practices, with a total follow-up time of 8.4 million patient years.
We recorded 29 491 incident cases of breast cancer in this
population. Table 2⇓ shows the incidence rates by age.
We identified 29 381 patients who received at least two
prescriptions for spironolactone after the age of 55 years. Of
these, 1349 patients had a history of breast cancer before their
index date (or an undated breast cancer record in nine cases)
and were excluded from the study. The exposed cohort consisted
of the remaining 28 032 patients, of whom 49.6% received at
least 12 prescriptions for spironolactone, 43.4% received a
maximum dose of 25 mg/day, and only 1.2% received more
than 200 mg/day (table 3⇓).
The index dates for patients in this study ranged from 1987 to
2010 (fig 1⇓). The increase in patient numbers over time was
partly the result of the recruitment of practices to the General
Practice Research Database. However, there was also a rapid
increase in the prescribing of spironolactone to women aged 55
years or more after 1999 (fig 2⇓).
We identified 55 961 control patients (99.8% of the target
number). They were matched to exposed patients on
socioeconomic score in the 202 practices that provided them.
Controls were also matched on exact year of birth in 53 647
(95.9%) cases. There was a maximum difference of five years
in all other cases (2314 (4.1%)). Mean follow-up time in the
study cohorts was 4.1 years.
Table 4⇓ shows the distribution of all the covariates in the
exposed and control cohorts. The use of oral contraceptives
within the observation periods available in the database was
low in both cohorts. The use of metformin, aspirin, steroids,
and drugs that could affect the development of gynaecomastia
was substantially higher in the spironolactone exposed cohort,
and this group used a greater number of drug classes. There was
a greater prevalence of diabetes and heart failure in the exposed
cohort. The prevalence of other cancers was slightly greater in
the exposed cohort, but a history of benign breast disease and
a family history of breast cancer were slightly less common.
Risk of breast cancer
We found no association between spironolactone use and risk
of breast cancer in our study population of women aged 55 years
or more. The exposed cohort of 28 032 patients and control
cohort of 55 961 patients had unadjusted incidence rates of
0.39% and 0.38% per year, respectively. In the primary analysis,
the hazard ratio in the exposed cohort versus the control cohort
was 0.99 (95% confidence interval 0.87 to 1.12). The significant
risk factors in this analysis were a family history of breast cancer
(3.87, 2.91 to 5.14), a history of other cancers (1.64, 1.44 to
1.87), exposure to multiple drug classes (1.04 per additional
class, 1.02 to 1.06), and exposure to steroids (0.78, 0.65 to 0.92).
Subgroup analyses did not show any group of patients in whom
spironolactone was a significant risk factor for breast cancer
(fig 3⇓). Excluding breast cancer in situ (40 (3%) cases) also
resulted in hazard ratios for spironolactone exposure close to
1, as did an analysis using a different control cohort constructed
using propensity scores on a subset of the covariates. We found
no evidence of a spironolactone dose response relation to risk
in the exposed cohort.
Discussion
Main findings
In this study, spironolactone use was not associated with any
increase in risk of new breast cancer in women in the UK aged
over 55 years with no previous history of breast cancer. Both
breast cancer incidence and the use of spironolactone increases
with age, hence our choice of study population, because it
included those patients most likely to be prescribed
spironolactone and also those most likely to develop breast
cancer. We cannot comment on whether spironolactone use in
younger women or inmen has any association with breast cancer
from these results. However, only two men within the General
Practice Research Database had both a diagnosis of breast cancer
and a history of exposure to spironolactone, suggesting that an
increased risk of male breast cancer with exposure to
spironolactone was unlikely, although the small number of cases
makes any study infeasible.
We looked at all incident breast cancers as our primary outcome
and all incident breast cancers excluding breast cancers in situ
as our secondary outcome, since in situ neoplasia could have a
different pathophysiology. However, we found no association
between spironolactone use and breast cancer for either outcome.
Comparison with other studies
This study adds to the findings of an earlier cohort study
reporting no association between spironolactone use and breast
cancer risk. The most recent International Agency for Research
on Cancer monograph on spironolactone summarises the known
human and animal toxicity data, including studies investigating
associations between spironolactone and other cancers.17
Administration of high dose spironolactone to rats increased
thyroid follicular cell adenomas and Leydig cell testicular
tumours, but reduced the incidence of
7,12-dimethylbenz[a]anthracene induced mammary tumours.
In one cohort study in humans, spironolactone was associated
with an excess risk of pharyngeal cancer, whereas a case-control
study found no association with thyroid cancer and five
case-control studies found that potassium sparing diuretics were
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not clearly identified as a risk factor for renal cell carcinoma
independently of hypertension. Further work with the General
Practice Research Database could revisit whether spironolactone
use is associated with increased risk of any other types of cancer,
particularly those with a hormonal basis such as prostate cancer
and thyroid cancer.
Indications for spironolactone have changed in the last few years
since earlier observational studies were done, with increasing
use in womenwith hypertension and heart failure and long term
use of lower doses. Recent observational studies investigating
associations between antihypertensive treatments and breast
cancer risk have failed to include spironolactone as a separate
variable. For example, a previous study in the General Practice
Research Database found no increased risk of breast cancer with
captopril and various other antihypertensive agents but
spironolactone was not specifically included, perhaps because
it is an unlicensed treatment for hypertension in the UK.18
Similarly, a Danish cohort study found no association between
breast cancer risk and the use of any antihypertensive treatment
or of individual classes of antihypertensive drug (diuretics, β
blockers, calcium channel blockers, angiotensin converting
enzyme inhibitors, and angiotensin II antagonists).19Conversely,
a case-control study in the United States found an association
between diuretic use and breast cancer risk.20 However, again
in these studies, spironolactone use was not specifically
examined. One study found a slight increase in risk of breast
cancer associated with use of potassium sparing diuretics, but
this category included both spironolactone and amiloride use.21
In addition, some studies have linked hypertension itself to risk
of breast cancer whereas others have found no association.22
Strengths and limitations
TheGeneral Practice ResearchDatabase includes a broad section
of patients from the primary care setting including a wide
geographical and socioeconomic distribution. Therefore, our
results should be largely generalisable to the postmenopausal
female population in the UK. However, because the study had
an observational design, all potential confounding factors might
not have been fully controlled for, despite matching on some
and adjusting for others. Although we found no link between
incident breast cancer and spironolactone exposure in this study,
we did not look at other outcomes and therefore cannot comment
on the general safety of spironolactone in women older than 55
years from our data.
Other limitations of this study could include the accuracy of
coding for the exposure, outcome, and covariates; and missing
data and confounding issues. Random errors were most likely
to arise from coding errors in the database, but these errors were
probably similar in both the exposed and unexposed cohorts.
The codes used for the study were crosschecked by the research
team, which included a breast cancer specialist and clinical
pharmacologists. Ideally, we would like to check the coding of
outcomes for study patients with UK Cancer Registry data.
Some risk factors for breast cancer (such as family history,
genetic abnormalities, information on breast feeding and parity,
age at menarche and menopause, and use of complementary
and recreational medications) were either unavailable or poorly
recorded in the General Practice Research Database and
therefore of limited use. However, we included all relevant
covariates for which data were available in our analyses. We
used sensitivity analyses to resolve potential problems of
misclassification, bias, and missing data.
Because of the difficulty in differentiating true recurrence of
breast cancer from re-reporting of previous breast cancer in the
records of the General Practice Research Database, we could
not do a sufficiently robust analysis of the hazards of
spironolactone in the 1340 women with a history of breast
cancer. However, accepting these limitations, we have
undertaken a matched cohort analysis in these patients with
prevalent breast cancer and judged the risk of recurrence as best
as we could. The adjusted hazard ratio was 0.88 (95%
confidence interval 0.64 to 1.21), suggesting no increase in
recurrence rates in women with previous breast cancer exposed
to spironolactone. Further research in this area should use more
detailed breast cancer databases.
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What is already known on this topic
Spironolactone use has increased substantially in recent years for conditions such as heart failure and resistant hypertension
The drug has progestogenic, antiandrogenic, and other less well defined effects on steroid receptors
However, there is concern that the drug could increase the risk of breast cancers and other cancers in humans
What this study adds
No increase in breast cancer risk was seen in women older than 55 years and with no history of breast cancer, after exposure to
spironolactone treatment
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Tables
Table 1| Read codes for breast cancer used to define primary outcome
DiagnosisRead code
Malignant neoplasm of female breastB34..00
Ca female breastB34..11
Malignant neoplasm of nipple and areola of female breastB340.00
Malignant neoplasm of nipple of female breastB340000
Malignant neoplasm of areola of female breastB340100
Malignant neoplasm of nipple or areola of female breast NOSB340z00
Malignant neoplasm of central part of female breastB341.00
Malignant neoplasm of upper-inner quadrant of female breastB342.00
Malignant neoplasm of lower-inner quadrant of female breastB343.00
Malignant neoplasm of upper-outer quadrant of female breastB344.00
Malignant neoplasm of lower-outer quadrant of female breastB345.00
Malignant neoplasm of axillary tail of female breastB346.00
Malignant neoplasm, overlapping lesion of breastB347.00
Malignant neoplasm of other site of female breastB34y.00
Malignant neoplasm of ectopic site of female breastB34y000
Malignant neoplasm of other site of female breast NOSB34yz00
Malignant neoplasm of female breast NOSB34z.00
Carcinoma in situ of breast and genitourinary systemB83..00
Carcinoma in situ of breastB830.00
Lobular carcinoma in situ of breastB830000
Intraductal carcinoma in situ of breastB830100
[M] Ductal, lobular, and medullary neoplasmsBB9..00
[M] Intraductal carcinoma, non-infiltrating NOSBB90.00
[M] Infiltrating duct carcinomaBB91.00
[M] Duct carcinoma NOSBB91.11
[M] Intraductal papillary adenocarcinoma with invasionBB91000
[M] Infiltrating duct and lobular carcinomaBB91100
[M] Comedocarcinoma, non-infiltratingBB92.00
[M] Comedocarcinoma NOSBB93.00
[M] Juvenile breast carcinomaBB94.00
[M] Secretory breast carcinomaBB94.11
[M] Medullary carcinoma NOSBB9B.00
[M] C cell carcinomaBB9B.11
[M] Medullary carcinoma with amyloid stromaBB9C.00
[M] Lobular carcinoma in situBB9E.00
[M] Intraductal carcinoma and lobular carcinoma in situBB9E000
[M] Lobular carcinoma NOSBB9F.00
[M] Infiltrating ductular carcinomaBB9G.00
[M] Inflammatory carcinomaBB9H.00
[M] Paget’s disease, mammaryBB9J.00
[M] Paget’s disease, breastBB9J.11
[M] Paget’s disease and infiltrating breast duct carcinomaBB9K.00
[M] Paget’s disease and intraductal carcinoma of breastBB9K000
[M] Paget’s disease, extramammary, excluding Paget’s disease boneBB9L.00
[M] Intracystic carcinoma NOSBB9M.00
[M] Ductal, lobular, or medullary neoplasm NOSBB9z.00
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Table 1 (continued)
DiagnosisRead code
M= morphology of neoplasms; NOS=not otherwise specified.
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Table 2| Incidence of breast cancer in study population of women aged 55 years or more
Incident cases of breast cancer
No of follow-up yearsAge (years) at start of year at risk Rate (% per year)Number
0.32461141 885 53655-59
0.36852381 424 01760-64
0.35545371 279 31465-69
0.31537461 188 02770-74
0.33935581 049 68275-79
0.3723022813 37280-84
0.4062049504 64885-89
0.434953219 84090-94
0.38927470 845≥95
0.35029 4918 435 281Total
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Table 3| Spironolactone prescriptions and maximum dose
No (%) of patients
28 032 (100.0)Total patients
13 911 (49.6)12 or more prescriptions
Maximum dose (mg/day)
12 179 (43.4)25
7384 (26.3)50
4822 (17.2)100
1022 (3.6)200
340 (1.2)>200
2285 (8.2)Unknown
5078 (18.1)First exposure before index date
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Table 4| Distribution of covariates in the exposed and control cohorts. Data are no (%) of patients unless stated otherwise
P
Cohort (no (%) of patients)
Control (n=55 961)Exposed (n=28 032)
Age (years)
1.0005570 (10.0)2786 (9.9)55-59
4152 (7.4)2076 (7.4)60-64
5395 (9.6)2699 (9.6)65-69
7236 (12.9)3619 (12.9)70 to 74
9487 (17.0)4748 (16.9)75 to 79
10 178 (18.2)5097 (18.2)80 to 84
13 943 (24.9)7007 (25.0)85 plus
Year of index date
1.0005396 (9.6)2702 (9.6)1987-94
5464 (9.8)2734 (9.8)1995-99
22 430 (40.1)11 228 (40.1)2000-04
22 671 (40.5)11 368 (40.6)2005-10
Townsend score (quintiles)
1.0004767 (8.5)2385 (8.5)1
4597 (8.2)2305 (8.2)2
4673 (8.4)2341 (8.4)3
4520 (8.1)2267 (8.1)4
3407 (6.1)1709 (6.1)5
33 997 (60.8)17 025 (60.7)Unknown
Known drug exposure before index date
0.391265 (0.5)145 (0.5)Oestrogen in oral contraceptives
0.086412 (0.7)177 (0.6)Progestogen without oestrogen in oral contraceptives
<0.0018547 (15.3)3947 (14.1)Oestrogen in hormone replacement therapy
<0.0012309 (4.1)2547 (9.1)Metformin
<0.00117 034 (30.4)12 460 (44.4)Aspirin
<0.00110 918 (19.5)9874 (35.2)Drugs that could affect development of gynaecomastia
<0.00130 571 (54.6)15 718 (56.1)Non-steroidal anti-inflammatory drugs
<0.0018095 (14.5)6988 (24.9)Steroids
Known medical history before index date
0.220382 (0.7)161 (0.6)Benign breast disease
<0.0017751 (13.9)4312 (15.4)Other cancers
<0.0016990 (12.5)6653 (23.7)Diabetes
<0.0015292 (9.5)12 188 (43.5)Heart failure
<0.00129 051 (51.9)16 067 (57.3)Hypertension
0.005539 (1.0)215 (0.8)Family history of breast cancer
Body mass index
<0.00111 181 (20.0)6261 (22.3)Unknown
4512 (8.1)2152 (7.7)7.8-<20.3
4825 (8.6)1823 (6.5)20.3-<22.1
4946 (8.8)1708 (6.1)22.1-<23.5
4863 (8.7)1797 (6.4)23.5-<24.8
4861 (8.7)1820 (6.5)24.8-<26.0
4640 (8.3)1984 (7.1)26.0-<27.4
4583 (8.2)2079 (7.4)27.4-<29.1
4338 (7.8)2310 (8.2)29.1-<31.2
4046 (7.2)2614 (9.3)31.2-<34.6
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Table 4 (continued)
P
Cohort (no (%) of patients)
Control (n=55 961)Exposed (n=28 032)
3166 (5.7)3484 (12.4)≥34.6
Alcohol consumption (units/week)
<0.00120 997 (37.5)10 703 (38.2)Unknown
18 525 (33.1)10 482 (37.4)0
4220 (7.5)1975 (7.0)1
4939 (8.8)1883 (6.7)2-4
4610 (8.2)1730 (6.2)5-10
2670 (4.8)1259 (4.5)>10
No of drug classes prescribed in year before index date
<0.00118 624 (33.3)2629 (9.4)0-2
21 628 (38.6)10 056 (35.9)3-5
12 398 (22.2)10 517 (37.5)6-8
3311 (5.9)4830 (17.2)≥9
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Figures
Fig 1 Distribution of index dates by year for 28 032 exposed patients and 55 961 control patients
Fig 2 Trends in spironolactone prescribing during study period
Fig 3 Risk of breast cancer in spironolactone users versus non-users, adjusted for significant covariates.
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